Vycor Medical, Inc. Announces Management Change
December 21 2012 - 5:00PM
Marketwired
Vycor Medical, Inc. ("Vycor" or "Company") (OTCBB: VYCO) announced
today that Richard Denness will resign as the Company's CEO
effective December 31, 2012, and as a member of the Board of
Directors effective immediately. Mr. Denness will remain as a
consultant to the Company during a transition period. The Board
will seek to appoint a successor CEO in due course.
Mr. Denness' decision to resign was strictly for personal
reasons and did not arise or result from any disagreement with the
Company on any matters relating to the Company's operations,
policies or practices.
Vycor has established a solid strategy for its Vycor Medical and
NovaVision divisions. Mr. Denness' duties will be absorbed by the
remaining executive team of the President, David Cantor, Executive
Vice-President Peter Zachariou and the Chairman and CFO, Adrian
Liddell.
About Vycor Medical, Inc.
Vycor Medical, Inc. is a medical device company committed to
making neurological brain, spinal and other surgical procedures
safer and more effective. The company's flagship patent pending
ViewSite™ Surgical Access Systems represent an exciting new
minimally invasive access and retraction system that holds the
potential for speedier, safer and more economical brain, spinal and
other surgeries and a quicker patient discharge. Vycor's innovative
medical instruments are designed to optimize neurosurgical site
access, reduce patient risk, accelerate recovery, and add tangible
value to the professional medical community. Vycor is ISO
13485:2003 compliant, has FDA 510(K) clearance for brain and spine
surgeries, and CE Marking and HPB licensing in Canada.
Vycor Medical's subsidiary, NovaVision, Inc., researches,
develops and provides science-driven vision-based neurostimulation
therapy and other medical technologies that help to improve sight
in patients with neurological vision impairments. The company's
proprietary Visual Restoration Therapy (VRT) platform is clinically
supported to improve lost vision resulting from stroke, traumatic
brain injury or other acquired brain injury, and has been 510(K)
cleared to be marketed in the US by the FDA. VRT can be prescribed
by any ophthalmologist, optometrist, neurologist or physiatrist.
NovaVision, through its subsidiary Sight Science, also provides
Neuro-Eye Therapy (NeET), aimed at increasing visual sensitivity
deep within the field defect. NovaVision also provides a fully
portable and ADA-compliant Head Mounted Perimeter (HMP™) which aids
in the detection and measurement of visual field deficits.
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words "forecast",
"anticipate", "estimate", "project", "intend", "expect", "should",
"believe", and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to known and unknown risks, uncertainties
and other factors which could cause Vycor Medical's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in Vycor Medical's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
Contact for Vycor Medical, Inc.: The Del Mar Consulting Group,
Inc. Robert B. Prag President 858-794-9500 Email Contact or Alex
Partners, LLC Scott Wilfong President 425-242-0891 Email
Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024